logo

Prothena Corporation Plc (PRTA)



Trade PRTA now with
  Date
  Headline
11/20/2017 6:31:21 AM Wedbush Downgrades Prothena Corporation plc (PRTA) To Neutral From Outperform With $55 Down From $75 Price Target
11/8/2017 1:00:33 PM RBC Capital Markets Is Cutting Prothena Corporation plc (PRTA) 4Q17 Estimate To -1.56 From -0.92
11/8/2017 12:59:25 PM RBC Capital Markets Is Lowering Prothena Corporation plc (PRTA) 2019 Estimate To -3.39 From -2.53
11/8/2017 12:59:08 PM RBC Capital Markets Is Lowering Prothena Corporation plc (PRTA) 2018 Estimate To -5.99 From -4.99
11/8/2017 12:57:30 PM RBC Capital Markets Is Raising Prothena Corporation plc (PRTA) 2017 Rev. Estimate To 27.3 M From 27.1 M
11/7/2017 6:17:47 PM Jefferies Is Lowering Prothena Corporation plc (PRTA) FY17 Rev. Estimate To 27.5 M From 27.7 M
11/7/2017 6:17:24 PM Jefferies Is Increasing Prothena Corporation plc (PRTA) FY18 Estimate To -6.26 From -6.82
11/7/2017 6:16:54 PM Jefferies Is Raising Prothena Corporation plc (PRTA) FY17 Estimate To -4.20 From -4.80
5/16/2017 4:06:34 PM Prothena Appoints Sarah Noonberg As Chief Medical Officer
5/11/2017 9:07:43 AM Wedbush Reiterates Prothena Corporation plc (PRTA) At Outperform With $75 Down From $77 Price Target
3/3/2017 8:32:26 AM Prothena Announces Pricing Of Public Offering Of 2.70 Mln Shares At $57.50/shr
2/15/2017 4:52:30 PM Wedbush Reiterates Prothena Corporation plc (PRTA) At Outperform With $77.00 Price Target